Edralbrutinib

DB18095InvestigationalSmall molecule

Edralbrutinib is an orally available small molecule inhibitor of Bruton's tyrosine kinase.

Mechanism: Pharmacologically active on Tyrosine-protein kinase BTK
Curator reviewed
Formula / weight: C₂₆H₂₁F₂N₅O₃ · 489.483 g/mol (avg)
Code names: SHR-1459 · TG-1701

Resolves to

Compound

Structure

InChIKeyDNPOFZXZJJDQLB-MRXNPFEDSA-NSMILESCC#CC(=O)N1CC[C@H](C1)N1C=C(C2=C1C(=O)NN=C2N)C1=CC=C(OC2=C(F)C=CC=C2F)C=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Edralbrutinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.